Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 22

1.

Clustering analysis of proteins from microbial genomes at multiple levels of resolution.

Zaslavsky L, Ciufo S, Fedorov B, Tatusova T.

BMC Bioinformatics. 2016 Aug 31;17 Suppl 8:276. doi: 10.1186/s12859-016-1112-8.

2.

NCBI prokaryotic genome annotation pipeline.

Tatusova T, DiCuccio M, Badretdin A, Chetvernin V, Nawrocki EP, Zaslavsky L, Lomsadze A, Pruitt KD, Borodovsky M, Ostell J.

Nucleic Acids Res. 2016 Aug 19;44(14):6614-24. doi: 10.1093/nar/gkw569. Epub 2016 Jun 24.

3.

Update on RefSeq microbial genomes resources.

Tatusova T, Ciufo S, Federhen S, Fedorov B, McVeigh R, O'Neill K, Tolstoy I, Zaslavsky L.

Nucleic Acids Res. 2015 Jan;43(Database issue):D599-605. doi: 10.1093/nar/gku1062. Epub 2014 Dec 15.

4.

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial.

Giovannoni G, Gold R, Selmaj K, Havrdova E, Montalban X, Radue EW, Stefoski D, McNeill M, Amaravadi L, Sweetser M, Elkins J, O'Neill G; SELECTION Study Investigators.

Lancet Neurol. 2014 May;13(5):472-81. doi: 10.1016/S1474-4422(14)70039-0. Epub 2014 Mar 19.

PMID:
24656609
5.

Virus Variation Resource--recent updates and future directions.

Brister JR, Bao Y, Zhdanov SA, Ostapchuck Y, Chetvernin V, Kiryutin B, Zaslavsky L, Kimelman M, Tatusova TA.

Nucleic Acids Res. 2014 Jan;42(Database issue):D660-5. doi: 10.1093/nar/gkt1268. Epub 2013 Dec 4.

6.

Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone.

Evdoshenko E, Maslyanskiy A, Lapin S, Zaslavsky L, Dobson R, Totolian A, Skoromets A, Bar-Or A.

ISRN Neurol. 2013 Sep 10;2013:748127. doi: 10.1155/2013/748127. eCollection 2013.

7.

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.

Gold R, Giovannoni G, Selmaj K, Havrdova E, Montalban X, Radue EW, Stefoski D, Robinson R, Riester K, Rana J, Elkins J, O'Neill G; SELECT study investigators.

Lancet. 2013 Jun 22;381(9884):2167-75. doi: 10.1016/S0140-6736(12)62190-4. Epub 2013 Apr 4.

PMID:
23562009
8.

Gastroretentive gabapentin (G-GR) formulation reduces intensity of pain associated with postherpetic neuralgia (PHN).

Sang CN, Sathyanarayana R, Sweeney M; DM-1796 Study Investigators.

Clin J Pain. 2013 Apr;29(4):281-8. doi: 10.1097/AJP.0b013e318258993e.

PMID:
22801243
9.

Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study.

Comi G, Abramsky O, Arbizu T, Boyko A, Gold R, Havrdová E, Komoly S, Selmaj K, Sharrack B, Filippi M; LAQ/5063 Study Group.

Mult Scler. 2010 Nov;16(11):1360-6. doi: 10.1177/1352458510378127. Epub 2010 Sep 8.

PMID:
20834039
10.

Mining the NCBI Influenza Sequence Database: adaptive grouping of BLAST results using precalculated neighbor indexing.

Zaslavsky L, Tatusova T.

Version 2. PLoS Curr. 2009 Oct 30 [revised 2009 Nov 4];1:RRN1124.

11.

Virus variation resources at the National Center for Biotechnology Information: dengue virus.

Resch W, Zaslavsky L, Kiryutin B, Rozanov M, Bao Y, Tatusova TA.

BMC Microbiol. 2009 Apr 2;9:65. doi: 10.1186/1471-2180-9-65.

12.

Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results.

Giovannoni G, Barbarash O, Casset-Semanaz F, King J, Metz L, Pardo G, Simsarian J, Sørensen PS, Stubinski B; Rebif New Formulation Study Group.

Mult Scler. 2009 Feb;15(2):219-28. doi: 10.1177/1352458508097299. Epub 2008 Aug 28.

PMID:
18755819
13.

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

Comi G, Pulizzi A, Rovaris M, Abramsky O, Arbizu T, Boiko A, Gold R, Havrdova E, Komoly S, Selmaj K, Sharrack B, Filippi M; LAQ/5062 Study Group.

Lancet. 2008 Jun 21;371(9630):2085-92. doi: 10.1016/S0140-6736(08)60918-6.

PMID:
18572078
14.

Visualization of large influenza virus sequence datasets using adaptively aggregated trees with sampling-based subscale representation.

Zaslavsky L, Bao Y, Tatusova TA.

BMC Bioinformatics. 2008 May 16;9:237. doi: 10.1186/1471-2105-9-237.

15.

The influenza virus resource at the National Center for Biotechnology Information.

Bao Y, Bolotov P, Dernovoy D, Kiryutin B, Zaslavsky L, Tatusova T, Ostell J, Lipman D.

J Virol. 2008 Jan;82(2):596-601. Epub 2007 Oct 17. No abstract available.

16.

Aspirin therapy is still underutilized among patients with type 2 diabetes.

Leitão CB, Krahe AL, Nabinger GB, Picon PX, Pecis M, Zaslavsky LM, Gross JL, Canani LH.

Arq Bras Endocrinol Metabol. 2006 Dec;50(6):1014-9.

17.

Visceral obesity is associated with higher urinary albumin excretion levels in normoalbuminuric type 2 diabetic patients.

Pecis M, Zaslavsky LM, Mallmann FB, Pante L, Krahe AL, Stringhari FF, Canani LH.

Arq Bras Endocrinol Metabol. 2006 Jun;50(3):466-71.

18.

Diastolic dysfunction and mortality in diabetic patients on hemodialysis: a 4.25-year controlled prospective study.

Zaslavsky LM, Pinotti AF, Gross JL.

J Diabetes Complications. 2005 Jul-Aug;19(4):194-200.

PMID:
15993352
19.

The odor specificities of a subset of olfactory receptor neurons are governed by Acj6, a POU-domain transcription factor.

Clyne PJ, Certel SJ, de Bruyne M, Zaslavsky L, Johnson WA, Carlson JR.

Neuron. 1999 Feb;22(2):339-47.

20.

Memory dysfunction and autonomic neuropathy in non-insulin-dependent (type 2) diabetic patients.

Zaslavsky LM, Gross JL, Chaves ML, Machado R.

Diabetes Res Clin Pract. 1995 Nov;30(2):101-10.

PMID:
8833630

Supplemental Content

Loading ...
Support Center